Neurogenetic Testing Market
Neurogenetic Testing Market Forecasts to 2030 - Global Analysis By Type (Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests and Other Types), By End User (Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories and Other End Users) and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $616.7 MN |
|
Projected Year Value (2030) |
US $1372.1 MN |
|
CAGR (2023 - 2030) |
12.1% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Neurogenetic Testing Market is accounted for $616.7 million in 2023 and is expected to reach $1,372.1 million by 2030 growing at a CAGR of 12.1% during the forecast period. Neurogenetic testing involves examining an individual's genetic makeup to identify specific genetic variations associated with neurological conditions. Its uses include diagnosing neurological disorders, assessing risk factors and guiding personalized treatment plans, leading to more targeted and effective healthcare interventions.
According to a WHO report, the European region contributes 11.2% of global burden of neurological disorder followed by Western Pacific region with 10%.
Market Dynamics:
Driver:
Rising prevalence of neurological disorders
The growing recognition and understanding of conditions like Alzheimer's, Parkinson's, and various neurodevelopmental disorders prompt a heightened demand for accurate and early genetic testing. Advances in neurogenetic testing provide a window into the genetic predispositions and risk factors for these conditions, facilitating early diagnosis and precise treatment planning. As these disorders gain prominence and medical understanding evolves, the need for effective neurogenetic testing becomes pivotal in tailoring interventions, enabling better management, and potentially averting or delaying the onset and progression of these challenging neurological conditions.
Restraint:
High costs associated with testing and limited accessibility
The complex nature of genetic testing methods, coupled with the need for specialized equipment and expertise, contributes to elevated testing costs, making these services unaffordable for many individuals. Additionally, limited accessibility to advanced neurogenetic tests, especially in underprivileged or remote regions, restricts the reach of these crucial diagnostic tools. As a result, disparities in access to cutting-edge healthcare solutions persist, preventing many from benefiting from early diagnosis, personalized treatment, and risk assessment for neurological conditions.
Opportunity:
Increasing research and development
Ongoing advancements in genetic testing technologies, coupled with deeper insights into the genetic underpinnings of neurological disorders, drive the development of more sophisticated, accurate, and comprehensive testing methods. This progress not only expands the scope of disorders that can be genetically tested but also enhances the precision and reliability of diagnostics. Moreover, it fuels the discovery of novel genetic markers and potential therapeutic targets, fostering the evolution of personalized medicine in neurology.
Threat:
The complexity of genetic testing methods
Genetic testing techniques, which often involve intricate processes like sequencing, microarray analysis, and interpretation of genetic variations, can be challenging to implement and comprehend. The need for highly specialized equipment, skilled professionals, and extensive bioinformatics analysis can lead to high operational costs, limiting accessibility to advanced testing. Additionally, the intricate nature of these tests may result in errors, data misinterpretation, or misdiagnoses, impacting their reliability and precision. Furthermore, the complexity of genetic testing can deter healthcare providers and patients from embracing these diagnostic tools, particularly in regions with limited technological infrastructure or healthcare expertise.
Covid-19 Impact:
The COVID-19 pandemic significantly impacted the market, driving both challenges and opportunities. While initial disruptions in supply chains and clinical operations affected testing accessibility, the urgency to understand neurological implications of the virus accelerated research and development in neurogenetics. Telehealth and remote testing gained prominence, facilitating patient access and diagnosis. This period underscored the importance of genetic testing in neurological disorders, prompting increased investment and innovation in testing technologies. Despite initial setbacks, the pandemic spurred advancements and a broader recognition of the critical role neurogenetic testing plays in healthcare, potentially reshaping the market's future landscape.
The polymerase chain reaction (PCR) tests segment is expected to be the largest during the forecast period
The polymerase chain reaction (PCR) test has a significant share in the market. PCR's ability to amplify DNA segments aids in detecting mutations linked to disorders like Huntington's disease or Parkinson's. Its high specificity and sensitivity empower accurate analysis of genetic markers, crucial in early diagnosis and disease monitoring. PCR's role extends to research, drug development, and personalized medicine within neurology, driving advancements in understanding the genetic basis of conditions. As a foundational tool, PCR tests continue to revolutionize neurogenetic testing, fostering insights that shape both research and clinical approaches.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospital has the highest CAGR within the market over the forecast period. They offer access to sophisticated testing facilities, allowing comprehensive genetic screenings, aiding in the identification of neurogenetic disorders. These institutions integrate testing into their diagnostic pathways, facilitating early disease detection and personalized treatment strategies. Hospitals also serve as centers for multidisciplinary collaboration, bringing together geneticists, neurologists, and other specialists to provide holistic care, contributing to ongoing research, and implementing cutting-edge testing methodologies, thereby significantly shaping the landscape of neurogenetic testing.
Region with largest share:
North America holds a significant position and expected to hold a largest share over the forecast period. The region houses leading biotech and pharmaceutical companies, fostering innovation and driving the development of cutting-edge testing methodologies. With a high prevalence of neurological disorders and a proactive healthcare system, North America witnesses extensive adoption of neurogenetic testing across clinical and research domains. The market in this region is characterized by a strong regulatory framework, strategic collaborations between academic institutions and industry, and a growing emphasis on personalized medicine, solidifying North America's position at the forefront of neurogenetic testing advancements.
Region with highest CAGR:
The Asia Pacific region witnessed highest CAGR in the market. With a large and diverse population, this region encounters a notable burden of neurological disorders, propelling the need for advanced diagnostic solutions. Furthermore, the presence of emerging economies and supportive government initiatives fosters collaborations between industry and research institutions, paving the way for expanded accessibility to testing and fueling the evolution of tailored approaches for diagnosing and managing neurological conditions in the Asia Pacific.
Key players in the market
Some of the key players in Neurogenetic Testing Market include Invitae Corporation, Ambry Genetics, PerkinElmer, GeneDx, Centogene, Blueprint Genetics, Genomic Health (Exact Sciences), Fulgent Genetics, QIAGEN and Baylor Genetics.
Key Developments:
In April 2023, Ambry Genetics and LifeStrands Genomics had collaborated to provide clinical genetic testing services in Singapore. Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore’s National Precision Medicine (NPM) programme through an open tender commissioned by Precision Health Research, Singapore (PRECISE) – the central entity implementing NPM.
In April 2023, Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research® (AACR) Annual Meeting 2023 in Orlando, Florida.
In August 2022, PerkinElmer has signed an agreement with private equity firm New Mountain Capital for the sale of its Applied, Food and Enterprise Services businesses for $2.45bn in cash to allow the company to focus on its high-margin Life Science and Diagnostics businesses.
Types Covered:
• Microarray Analysis
• Whole-Exome Sequencing (WES)
• Multiplex Ligation Dependent Probe Amplification (MLPA)
• Polymerase Chain Reaction (PCR) Tests
• Other Types
End Users Covered:
• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostics Laboratories
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neurogenetic Testing Market, By Type
5.1 Introduction
5.2 Microarray Analysis
5.3 Whole-Exome Sequencing (WES)
5.4 Multiplex Ligation Dependent Probe Amplification (MLPA)
5.5 Polymerase Chain Reaction (PCR) Tests
5.6 Other Types
6 Global Neurogenetic Testing Market, By End User
6.1 Introduction
6.2 Hospitals
6.3 Specialty Clinics
6.4 Research Institutes
6.5 Diagnostics Laboratories
6.6 Other End Users
7 Global Neurogenetic Testing Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Invitae Corporation
9.2 Ambry Genetics
9.3 PerkinElmer
9.4 GeneDx
9.5 Centogene
9.6 Blueprint Genetics
9.7 Genomic Health (Exact Sciences)
9.8 Fulgent Genetics
9.9 QIAGEN
9.10 Baylor Genetics
List of Tables
1 Global Neurogenetic Testing Market Outlook, By Region (2021-2030) ($MN)
2 Global Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
3 Global Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
4 Global Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
5 Global Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
6 Global Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
7 Global Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
8 Global Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
9 Global Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
10 Global Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
11 Global Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
12 Global Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
13 Global Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
14 North America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
15 North America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
16 North America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
17 North America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
18 North America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN) 19 North America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
20 North America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
21 North America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
22 North America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
23 North America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
24 North America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
25 North America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
26 North America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
27 Europe Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
28 Europe Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
29 Europe Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
30 Europe Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
31 Europe Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
32 Europe Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
33 Europe Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
34 Europe Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
35 Europe Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
36 Europe Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
37 Europe Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
38 Europe Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
39 Europe Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
40 Asia Pacific Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
41 Asia Pacific Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
42 Asia Pacific Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
43 Asia Pacific Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
44 Asia Pacific Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
45 Asia Pacific Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
46 Asia Pacific Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
47 Asia Pacific Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
48 Asia Pacific Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
49 Asia Pacific Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
50 Asia Pacific Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
51 Asia Pacific Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
52 Asia Pacific Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
53 South America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
54 South America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
55 South America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
56 South America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
57 South America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
58 South America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
59 South America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
60 South America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
61 South America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
62 South America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
63 South America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
64 South America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
65 South America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
66 Middle East & Africa Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
67 Middle East & Africa Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
68 Middle East & Africa Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
69 Middle East & Africa Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
70 Middle East & Africa Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
71 Middle East & Africa Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
72 Middle East & Africa Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
73 Middle East & Africa Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
74 Middle East & Africa Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
75 Middle East & Africa Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
76 Middle East & Africa Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
77 Middle East & Africa Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
78 Middle East & Africa Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
